ReviewExperimental biology and medicine (Maywood, N.J.)2014
Erythropoietin: powerful protection of ischemic and post-ischemic brain.
Review in Experimental biology and medicine (Maywood, N.J.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Harms of off-label erythropoiesis-stimulating agents for critically ill people.The Cochrane database of systematic reviews · 2017Pooled it
- Neuroprotective properties of erythropoietin (Epo) and its receptor (EpoR) in open spinal dysraphism (OSD): an investigation of EpoR expression in a rat OSD model, along with in vitro studies on the neuroprotective effects of Epo on rat spinal cord-derived neural progenitor cells.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025Article
- Molecular Aspects of Volatile Anesthetic-Induced Organ Protection and Its Potential in Kidney Transplantation.International journal of molecular sciences · 2021Review
- Activation and Role of Astrocytes in Ischemic Stroke.Frontiers in cellular neuroscience · 2021Review
- Treatment and new progress of neonatal hypoxic-ischemic brain damage.Histology and histopathology · 2020Review
- Regulation of muscle and metabolic physiology by hypothalamic erythropoietin independently of its peripheral action.Molecular metabolism · 2020Article
- Intranasal Erythropoietin Protects CA1 Hippocampal Cells, Modulated by Specific Time Pattern Molecular Changes After Ischemic Damage in Rats.Journal of molecular neuroscience : MN · 2019Article
- Intracerebral transplantation of erythropoietin-producing fibroblasts facilitates neurogenesis and functional recovery in an ischemic stroke model.Brain and behavior · 2019Article
- The Recombinant Human Erythropoietin Administered in Neonatal Rats After Excitotoxic Damage Induces Molecular Changes in the Hippocampus.Frontiers in neuroscience · 2019Article
- Chorioamnionitis, neuroinflammation, and injury: timing is key in the preterm ovine fetus.Journal of neuroinflammation · 2018Article
- Neuroprotective Effects of neuroEPO Using an In Vitro Model of Stroke.Behavioral sciences (Basel, Switzerland) · 2018Article
- Transfection of primary brain capillary endothelial cells for protein synthesis and secretion of recombinant erythropoietin: a strategy to enable protein delivery to the brain.Cellular and molecular life sciences : CMLS · 2017Article
- Featured Article: Pyruvate preserves antiglycation defenses in porcine brain after cardiac arrest.Experimental biology and medicine (Maywood, N.J.) · 2017Article
- Intermittent hypoxic-hyperoxic training on cognitive performance in geriatric patients.Alzheimer's & dementia (New York, N. Y.) · 2017Article
- Vascular hypoperfusion in acute optic neuritis is a potentially new neurovascular model for demyelinating diseases.PloS one · 2017Article
- The role of erythropoietin in remote renal preconditioning on hippocampus ischemia/reperfusion injury.The journal of physiological sciences : JPS · 2017Article
- Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders.British journal of clinical pharmacology · 2016Review
- Erythropoietin production by PDGFR-β(+) cells.Pflugers Archiv : European journal of physiology · 2016Article
- Intermittent hypoxia training protects cerebrovascular function in Alzheimer's disease.Experimental biology and medicine (Maywood, N.J.) · 2016Article
- Erythropoietin Pathway: A Potential Target for the Treatment of Depression.International journal of molecular sciences · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Ischemic brain injury inflicted by stroke and cardiac arrest ranks among the leading causes of death and long-term disability in the United States. The brain consumes large amounts of metabolic substrates and oxygen to sustain its energy requirements. Consequently, the brain is exquisitely sensitive to interruptions in its blood supply, and suffers irreversible damage after 10-15 min of severe ischemia. Effective treatments to protect the brain from stroke and cardiac arrest have proven elusive, due to the complexities of the injury cascades ignited by ischemia and reperfusion. Although recombinant tissue plasminogen activator and therapeutic hypothermia have proven efficacious for stroke and cardiac arrest, respectively, these treatments are constrained by narrow therapeutic windows, potentially detrimental side-effects and the limited availability of hypothermia equipment. Mounting evidence demonstrates the cytokine hormone erythropoietin (EPO) to be a powerful neuroprotective agent and a potential adjuvant to established therapies. Classically, EPO originating primarily in the kidneys promotes erythrocyte production by suppressing apoptosis of proerythroid progenitors in bone marrow. However, the brain is capable of producing EPO, and EPO's membrane receptors and signaling components also are expressed in neurons and astrocytes. EPO activates signaling cascades that increase the brain's resistance to ischemia-reperfusion stress by stabilizing mitochondrial membranes, limiting formation of reactive oxygen and nitrogen intermediates, and suppressing pro-inflammatory cytokine production and neutrophil infiltration. Collectively, these mechanisms preserve functional brain tissue and, thus, improve neurocognitive recovery from brain ischemia. This article reviews the mechanisms mediating EPO-induced brain protection, critiques the clinical utility of exogenous EPO to preserve brain threatened by ischemic stroke and cardiac arrest, and discusses the prospects for induction of EPO production within the brain by the intermediary metabolite, pyruvate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.